Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Flagstar Bank NA (FLG) vs 10X Genomics Inc (TXG) Price & Performance

Flagstar Bank NATrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Flagstar Bank NA vs 10X Genomics Inc — how do they compare? Flagstar Bank NA trades at $11.36 (market cap $4.71B), while 10X Genomics Inc trades at $79.21 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 2.1× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.35% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 21 Days and 10X Genomics Inc for 92 Days on average.

FLGTXG
Market Cap
$4.71B$10.07B
Volume
7,410,5895,657,286
Sector
FinancialsHealth
52-Week High
$15.36$97.74
52-Week Low
$10.72$11.48
Typical Hold Time
21 Days92 Days
Enterprise Value
$15.25B$9.59B
Dividend Yield
0.35%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flagstar Bank NA

Flagstar Bank (FLG) trades at $11.30, down 2.25% on the day, with a bearish technical outlook despite recent earnings beats. The company shows improving fundamentals with Q2 2026 marking the third consecutive profitable quarter, though it missed EPS estimates. Analyst sentiment remains positive with a $17.07 consensus price target representing 51% upside potential. Recent strategic developments include a $250 million share repurchase program and a new core banking partnership with Fiserv.

The stock presents a compelling value opportunity trading at 0.62x book value, but faces risks from volatile earnings performance and negative cash flow trends. While analyst consensus is bullish with 60% buy ratings, investors should monitor execution on profitability improvements and the impact of recent strategic initiatives on long-term growth.

10X Genomics Inc

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FLG

No sentiment data available yet.

TXG
4% Buy96% Sell
Avg holding period · 92 Days

Top news

Latest headlines on both assets

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →